Research so far shows that Novavax, like mRNA vaccines, may also carry this rare side effect though. Following high levels of ...

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2024. Novavax, Inc. (Nasdaq: NVAX), a ...

Bullish option flow detected in Novavax (NVAX) with 23,789 calls trading, 3x expected, and implied vol increasing over 8 points to 114.25%. Feb-25 8.5 calls and Mar-25 7.5 puts are the most active ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax (NVAX) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%.

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, the company’s earnings beat estimates by 12.64%. The Zacks Consensus ...

Erica Kollmann Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline.

Or you can visit the pharmacy's website directly. All vaccines authorized by the FDA last summer -- Moderna, Pfizer and Novavax -- target a strain of virus that is a better match for the one ...